Sbarro Health Research Organization (SHRO) shared a post on LinkedIn:
“New hope in the fight against Triple-Negative Breast Cancer (TNBC)
A new study from the Senology Department at Italy’s National Cancer Institute Pascale Foundation, in collaboration with the Sbarro Institute for Cancer Research and Molecular Medicine (Philadelphia), has uncovered a promising new therapeutic target for one of the most aggressive and hard-to-treat forms of breast cancer.
The research, published in the International Journal of Molecular Sciences, highlights the role of the NONO protein, found in unusually high levels in TNBC cells. By reducing NONO—either through gene-silencing (siRNA) or chemical inhibitors—researchers were able to “wake up” the body’s natural immune defenses, paving the way for new treatment strategies.
This opens exciting possibilities for combining NONO inhibitors with immune checkpoint modulators, drugs already proven effective in other cancers. While preliminary, the findings point to a much-needed new direction for TNBC patients.
Congratulations to Prof. Michelino De Laurentiis, Luigi Alfano, Carmelina Iannuzzi, and long-time international collaborator Prof. Antonio Giordano for this groundbreaking work.
This discovery reinforces Pascale’s global reputation for excellence in oncology research and the commitment to improving care for patients worldwide.”